Shots:

• Supernus signs a definitive agreement to acquire Adamas for $8.10/ share in cash (~$400M) & 2 non-tradable CVR of ~$1.00 00/share in cash (~$50M) based on sales of GOCOVRI- making a total deal value of $9.10/share in cash (~$450M). The transaction is expected to close in Q4’21 or Q1’22
• The 1st & 2nd CVR cost of $0.50/share- upon achievement of net sales of Gocovri for $150M & $225M in any 4 consecutive quarters at end of 2024 & 2025 respectively
• The acquisition will offer Supernus with 2 marketed products i.e.- Gocovri ER capsules for OFF & dyskinesia in patients with PD receiving levodopa-based therapy & Osmolex ER tablets for PD & drug-induced extrapyramidal reactions in adult patients

  | Ref: Supernus | Image: Businesswire